Market Overview

UPDATE: Bank of America Raises PO to $40 on Integra Lifesciences

Related IART
Integra LifeSciences Announces Changes Within Its Orthopedics And Tissue Technologies Business
Integra LifeSciences Announces Renewal And Extension Of Credit Facility; Increased From $600M to $900M
EMCORE Selling Space Solar Business to Veritas Capital (Fox Business)

Bank of America Merrill Lynch reiterates a Neutral rating on Integra Lifesciences (NASDAQ: IART) and raises its price objective from $36 to $40.

Bank of America Merrill Lynch comments, “Raising PO to $40 We are raising our PO on IART to $40 from $36 primarily due to the recent signs of stabilization and/or strength in IART's most important orthopedic growth markets (extremities/spine) that we have documented in recent notes on Biomet and ZMH. Additionally, IART, like many US-focused small cap device names, would benefit in a disproportionate way if the Supreme Court declares President Obama's healthcare reform law unconstitutional this week (a decision is expected Thursday 6/28).”

Integra Lifesciences closed at $35.74 yesterday.

Latest Ratings for IART

DateFirmActionFromTo
Aug 2014OppenheimerMaintainsOutperform
May 2014OppenheimerMaintainsOutperform
Apr 2014Lake Street CapitalInitiates Coverage onBuy

View More Analyst Ratings for IART
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color News Price Target Politics Legal Analyst Ratings General

 

Related Articles (IART)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters